Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 7070469, 9 pages
https://doi.org/10.1155/2017/7070469
Research Article

Neuroinflammation and ALS: Transcriptomic Insights into Molecular Disease Mechanisms and Therapeutic Targets

Institute of Neurological Sciences, Italian National Research Council, Catania, Italy

Correspondence should be addressed to Sebastiano Cavallaro; ti.rnc@orallavac.onaitsabes

Received 20 March 2017; Revised 23 June 2017; Accepted 11 July 2017; Published 7 September 2017

Academic Editor: Thomas Möller

Copyright © 2017 Giovanna Morello et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Mitchell and G. D. Borasio, “Amyotrophic lateral sclerosis,” Lancet, vol. 369, no. 9578, pp. 2031–2041, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Eisen, “Amyotrophic lateral sclerosis-evolutionary and other perspectives,” Muscle & Nerve, vol. 40, no. 2, pp. 297–304, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. C. L. Simpson and A. Al Chalabi, “Amyotrophic lateral sclerosis as a complex genetic disease,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1762, no. 11-12, pp. 973–985, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. P. M. Andersen and A. Al-Chalabi, “Clinical genetics of amyotrophic lateral sclerosis: what do we really know?” Nature Reviews Neurology, vol. 7, no. 11, pp. 603–615, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Armon, “Environmental risk factors for amyotrophic lateral sclerosis,” Neuroepidemiology, vol. 20, no. 1, pp. 2–6, 2001. View at Publisher · View at Google Scholar
  6. D. Majoor-Krakauer, P. J. Willems, and A. Hofman, “Genetic epidemiology of amyotrophic lateral sclerosis,” ClinicalGenetics, vol. 63, no. 2, pp. 83–101, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. P. G. Ince, J. R. Highley, J. Kirby et al., “Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology,” Acta Neuropathologica, vol. 122, no. 6, pp. 657–671, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. D. R. Rosen, “Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis,” Nature, vol. 364, no. 6435, p. 362, 1993. View at Publisher · View at Google Scholar
  9. S. Hadano, C. K. Hand, H. Osuga et al., “A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2,” Nature Genetics, vol. 29, no. 2, pp. 166–173, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Z. Chen, C. L. Bennett, H. M. Huynh et al., “DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4),” The American Journal of Human Genetics, vol. 74, no. 6, pp. 1128–1135, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. P. F. Chance, B. A. Rabin, S. G. Ryan et al., “Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34,” The American Journal of Human Genetics, vol. 62, no. 3, pp. 633–640, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Orlacchio, C. Babalini, A. Borreca et al., “SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis,” Brain, vol. 133, Part 2, pp. 591–598, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Vance, B. Rogelj, T. Hortobagyi et al., “Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6,” Science, vol. 323, no. 5918, pp. 1208–1211, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. T. J. Kwiatkowski Jr., D. A. Bosco, A. L. Leclerc et al., “Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis,” Science, vol. 323, no. 5918, pp. 1205–1208, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. L. Nishimura, M. Mitne-Neto, H. C. Silva et al., “A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis,” The American Journal of Human Genetics, vol. 75, no. 5, pp. 822–831, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. M. J. Greenway, P. M. Andersen, C. Russ et al., “ANG mutations segregate with familial and ‘sporadic’ amyotrophic lateral sclerosis,” Nature Genetics, vol. 38, no. 4, pp. 411–413, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. H. J. Chen, G. Anagnostou, A. Chai et al., “Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis,” The Journal of Biological Chemistry, vol. 285, no. 51, pp. 40266–40281, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Sreedharan, I. P. Blair, V. B. Tripathi et al., “TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis,” Science, vol. 319, no. 5870, pp. 1668–1672, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. M. A. Gitcho, R. H. Baloh, S. Chakraverty et al., “TDP-43 A315T mutation in familial motor neuron disease,” Annals of Neurology, vol. 63, no. 4, pp. 535–538, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Kabashi, P. N. Valdmanis, P. Dion et al., “TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis,” Nature Genetics, vol. 40, no. 5, pp. 572–574, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Y. Chow, J. E. Landers, S. K. Bergren et al., “Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS,” American Journal of Human Genetics, vol. 84, no. 1, pp. 85–88, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. M. A. van Es, F. P. Diekstra, J. H. Veldink et al., “A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation,” Neurology, vol. 72, no. 3, pp. 287-288, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. A. C. Elden, H. J. Kim, M. P. Hart et al., “Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS,” Nature, vol. 466, no. 7310, pp. 1069–1075, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. DeJesus-Hernandez, I. R. Mackenzie, B. F. Boeve et al., “Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS,” Neuron, vol. 72, no. 2, pp. 245–256, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. A. E. Renton, E. Majounie, A. Waite et al., “A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD,” Neuron, vol. 72, no. 2, pp. 257–268, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Guareschi, E. Cova, C. Cereda et al., “An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 13, pp. 5074–5079, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Cluskey and D. B. Ramsden, “Mechanisms of neurodegeneration in amyotrophic lateral sclerosis,” Molecular Pathology, vol. 54, no. 6, pp. 386–392, 2001. View at Google Scholar
  28. A. Malaspina, N. Kaushik, and J. de Belleroche, “Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays,” Journal of Neurochemistry, vol. 77, no. 1, pp. 132–145, 2001. View at Google Scholar
  29. Y. M. Jiang, M. Yamamoto, Y. Kobayashi et al., “Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis,” Annals of Neurology, vol. 57, no. 2, pp. 236–251, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Dangond, D. Hwang, S. Camelo et al., “Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter,” Physiological Genomics, vol. 16, no. 2, pp. 229–239, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Offen, Y. Barhum, E. Melamed, N. Embacher, C. Schindler, and G. Ransmayr, “Spinal cord mRNA profile in patients with ALS: comparison with transgenic mice expressing the human SOD-1 mutant,” Journal of Molecular Neuroscience, vol. 38, no. 2, pp. 85–93, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. X. S. Wang, Z. Simmons, W. Liu, P. J. Boyer, and J. R. Connor, “Differential expression of genes in amyotrophic lateral sclerosis revealed by profiling the post mortem cortex,” Amyotrophic Lateral Sclerosis, vol. 7, no. 4, pp. 201–210, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. C. W. Lederer, A. Torrisi, M. Pantelidou, N. Santama, and S. Cavallaro, “Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis,” BMC Genomics, vol. 8, no. 1, p. 26, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. S. J. Rabin, J. M. Kim, M. Baughn et al., “Sporadic ALS has compartment-specific aberrant exon splicing and altered cell-matrix adhesion biology,” Human Molecular Genetics, vol. 19, no. 2, pp. 313–328, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. L. E. Cox, L. Ferraiuolo, E. F. Goodall et al., “Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS),” PLoS One, vol. 5, no. 3, article e9872, 2010. View at Google Scholar
  36. S. Morgan and R. W. Orrell, “Pathogenesis of amyotrophic lateral sclerosis,” British Medical Bulletin, vol. 119, no. 1, pp. 87–98, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. W. Robberecht and T. Philips, “The changing scene of amyotrophic lateral sclerosis,” Nature Reviews Neuroscience, vol. 14, no. 4, pp. 248–264, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. P. A. McCombe and R. D. Henderson, “The role of immune and inflammatory mechanisms in ALS,” Current Molecular Medicine, vol. 11, no. 3, pp. 246–254, 2011. View at Publisher · View at Google Scholar
  39. K. G. Hooten, D. R. Beers, W. Zhao, and S. H. Appel, “Protective and toxic neuroinflammation in amyotrophic lateral sclerosis,” Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics, vol. 12, no. 2, pp. 364–375, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Rizzo, G. Riboldi, S. Salani et al., “Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis,” Cellular and Molecular Life Sciences: CMLS, vol. 71, no. 6, pp. 999–1015, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Malaspina, F. Puentes, and S. Amor, “Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective,” International Immunology, vol. 27, no. 3, pp. 117–129, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Aronica, F. Baas, A. Iyer, A. L. ten Asbroek, G. Morello, and S. Cavallaro, “Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex,” Neurobiology of Disease, vol. 74, pp. 359–376, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Morello and S. Cavallaro, “Transcriptional analysis reveals distinct subtypes in amyotrophic lateral sclerosis: implications for personalized therapy,” Future Medicinal Chemistry, vol. 7, no. 10, pp. 1335–1359, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. M. A. Harris, J. Clark, A. Ireland et al., “The Gene Ontology (GO) database and informatics resource,” Nucleic Acids Research, vol. 32, Database issue, pp. D258–D261, 2004. View at Publisher · View at Google Scholar
  45. D. Szklarczyk, A. Franceschini, S. Wyder et al., “STRING v10: protein-protein interaction networks, integrated over the tree of life,” Nucleic Acids Research, vol. 43, Database issue, pp. D447–D452, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Santos, K. Tsafou, C. Stolte, S. Pletscher-Frankild, S. I. O’Donoghue, and L. J. Jensen, “Comprehensive comparison of large-scale tissue expression datasets,” PeerJ, vol. 3, article e1054, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Assenov, F. Ramirez, S. E. Schelhorn, T. Lengauer, and M. Albrecht, “Computing topological parameters of biological networks,” Bioinformatics, vol. 24, no. 2, pp. 282–284, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. Y. Nikolsky, S. Ekins, T. Nikolskaya, and A. Bugrim, “A novel method for generation of signature networks as biomarkers from complex high throughput data,” Toxicology Letters, vol. 158, no. 1, pp. 20–29, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. T. Bleazard, J. A. Lamb, and S. Griffiths-Jones, “Bias in microRNA functional enrichment analysis,” Bioinformatics, vol. 31, no. 10, pp. 1592–1598, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Riva, F. Clarelli, T. Domi et al., “Unraveling gene expression profiles in peripheral motor nerve from amyotrophic lateral sclerosis patients: insights into pathogenesis,” Scientific Reports, vol. 6, article 39297, 2016. View at Publisher · View at Google Scholar · View at Scopus
  51. A. A. Bergen, S. Kaing, J. B. ten Brink, B. Netherlands Brain, T. G. Gorgels, and S. F. Janssen, “Gene expression and functional annotation of human choroid plexus epithelium failure in Alzheimer’s disease,” BMC Genomics, vol. 16, p. 956, 2015. View at Publisher · View at Google Scholar · View at Scopus
  52. L. Petrucelli and T. M. Dawson, “Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system,” Annals of Medicine, vol. 36, no. 4, pp. 315–320, 2004. View at Google Scholar
  53. C. A. Ross and M. A. Poirier, “Protein aggregation and neurodegenerative disease,” Nature Medicine, Supplement 10, pp. S10–S17, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Hanrieder, T. Ekegren, M. Andersson, and J. Bergquist, “MALDI imaging of post-mortem human spinal cord in amyotrophic lateral sclerosis,” Journal of Neurochemistry, vol. 124, no. 5, pp. 695–707, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. N. L. Lehman, “The ubiquitin proteasome system in neuropathology,” Acta Neuropathologica, vol. 118, no. 3, pp. 329–347, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. G. P. de Oliveira, C. J. Alves, and G. Chadi, “Early gene expression changes in spinal cord from SOD1 (G93A) amyotrophic lateral sclerosis animal model,” Frontiers in Cellular Neuroscience, vol. 7, p. 216, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. C. A. Lewis, J. Manning, F. Rossi, and C. Krieger, “The neuroinflammatory response in ALS: the roles of microglia and T cells,” Neurology Research International, vol. 2012, Article ID 803701, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Bahia El Idrissi, S. Bosch, V. Ramaglia, E. Aronica, F. Baas, and D. Troost, “Complement activation at the motor end-plates in amyotrophic lateral sclerosis,” Journal of Neuroinflammation, vol. 13, no. 1, p. 72, 2016. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Rentzos, A. Rombos, C. Nikolaou et al., “Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation?” Acta Neurologica Scandinavica, vol. 122, no. 6, pp. 425–429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Tateishi, R. Yamasaki, M. Tanaka et al., “CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis,” Journal of Neuroimmunology, vol. 222, no. 1-2, pp. 76–81, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. J. K. Lee, J. H. Shin, J. E. Lee, and E. J. Choi, “Role of autophagy in the pathogenesis of amyotrophic lateral sclerosis,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1852, no. 11, pp. 2517–2524, 2015. View at Publisher · View at Google Scholar · View at Scopus
  62. J. A. Oakes, M. C. Davies, and M. O. Collins, “TBK1: a new player in ALS linking autophagy and neuroinflammation,” Molecular Brain, vol. 10, no. 1, p. 5, 2017. View at Publisher · View at Google Scholar
  63. Y. K. Moliaka, A. Grigorenko, D. Madera, and E. I. Rogaev, “Impas 1 possesses endoproteolytic activity against multipass membrane protein substrate cleaving the presenilin 1 holoprotein,” FEBS Letters, vol. 557, no. 1–3, pp. 185–192, 2004. View at Google Scholar